Somewhat Favorable News Coverage Somewhat Unlikely to Affect Akorn (AKRX) Share Price
Media coverage about Akorn (NASDAQ:AKRX) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akorn earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.3561535745309 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Akorn, Inc. (NASDAQ:AKRX) Trading Up – Short interest grew by … – Highlight Press (highlightpress.com)
- A Few Clear Signs For Huntington Bancshares Incorporated (HBAN), Akorn, Inc. (AKRX) – AllStockNews (allstocknews.com)
- Trading Indicator Review for Akorn Inc (AKRX) – Wall Street Review (thewallstreetreview.com)
- Akorn, Inc. (AKRX) 19.76% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Top Stock Picks for the Day: Akorn, Inc. (AKRX), Weight Watchers International, Inc. (WTW) – AllStockNews (allstocknews.com)
Several research firms have weighed in on AKRX. Piper Jaffray Companies set a $34.00 target price on shares of Akorn and gave the stock a “hold” rating in a report on Tuesday, August 29th. Zacks Investment Research lowered shares of Akorn from a “hold” rating to a “strong sell” rating in a report on Friday, August 25th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $34.00 target price on shares of Akorn in a report on Sunday, August 20th. BidaskClub lowered shares of Akorn from a “sell” rating to a “strong sell” rating in a report on Saturday, August 19th. Finally, TheStreet lowered shares of Akorn from a “b-” rating to a “c” rating in a report on Tuesday, August 1st. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $28.56.
Shares of Akorn (NASDAQ AKRX) opened at 32.94 on Friday. Akorn has a 52 week low of $17.61 and a 52 week high of $34.00. The firm has a 50-day moving average of $33.20 and a 200 day moving average of $30.43. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of 33.27 and a beta of 1.38.
In other Akorn news, Director Brian Tambi sold 5,165 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $33.37, for a total transaction of $172,356.05. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Bruce Kutinsky sold 40,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $33.46, for a total transaction of $1,338,400.00. Following the transaction, the chief operating officer now owns 317,480 shares in the company, valued at approximately $10,622,880.80. The disclosure for this sale can be found here. Corporate insiders own 28.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Akorn (AKRX) Share Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/03/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-akorn-akrx-share-price.html.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Stock Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related stocks with our FREE daily email newsletter.